# Cancer Immunology Program

> **NIH NIH P30** · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · 2020 · $79,592

## Abstract

Cancer Immunology Program: Summary
The mission of the Cancer Immunology (CI) Program is to understand the molecular basis and dynamic
relationship between the immune system and cancer in order to translate this knowledge into novel and
improved therapeutics.
The CI Program has been restructured to focus on the pipeline from cancer immunology to immunotherapy,
with research spanning from basic mechanistic studies in mouse models to investigating the response of the
immune system in cancer patients receiving the latest immune-based therapeutics in the clinic. The CI
Program has been strengthened by the establishment of the HDFCCC Cancer Immunotherapy Research Clinic
in April 2016, allowing a more systematic evaluation of patients receiving immunotherapies as standard of care
or as part of prospective clinical trials. In doing so, the goal is to enhance the efficacy of these approaches, but
also to avoid the toxicities associated with the current generation of checkpoint blockade and CAR T cell-based
therapies. CI Program members have made significant new scientific findings in the field of cancer immunology,
particularly with respect to understanding the tumor microenvironment and basic mechanisms of interactions
between immune cells and tumors. Program members have recently made many important contributions to the
understanding of the interplay between the immune system and tumors, crossing each of the three themes.
Theme 1: Identifying Immune System Mechanisms that Regulate Cancer Initiation and Progression
Theme 2: Defining the Role of the Tumor Microenvironment in Cancer Immunity
Theme 3: Developing Novel Approaches to Cancer Immunotherapy and Understanding Mechanisms
Underlying their Efficacy and Toxicities
CI Program: Key Metrics
Membership (12 departments, 2 schools) 23
Full 17
Associate 6
Cancer-relevant Funding (direct costs as of
$24,118,432
05/31/2017)
NCI $4,117,666 17%
Peer-reviewed $6,463,606 27%
Non-peer-reviewed $13,537,159 56%
Cancer-relevant Publications (1/2012-7/2017) 419
Inter-programmatic 96 23%
Intra-Programmatic 38 9%
High-Impact 177 42%
Accruals to Clinical Trials (2016) 124
Therapeutic 124 30
Other Interventional 0 0
Non-interventional 0 0

## Key facts

- **NIH application ID:** 9965771
- **Project number:** 5P30CA082103-21
- **Recipient organization:** UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
- **Principal Investigator:** LEWIS Lee LANIER
- **Activity code:** P30 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2020
- **Award amount:** $79,592
- **Award type:** 5
- **Project period:** — → —

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/9965771

## Citation

> US National Institutes of Health, RePORTER application 9965771, Cancer Immunology Program (5P30CA082103-21). Retrieved via AI Analytics 2026-05-22 from https://api.ai-analytics.org/grant/nih/9965771. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*